Levosimendan Kalceks (Levosimendan)

Levosimendan works by binding to troponin C, making the heart muscle more sensitive to existing calcium, which strengthens each contraction without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces the workload on the heart.

The dosing regimen for levosimendan is individualized and determined by the prescribing clinician based on the patient’s clinical status, weight, and renal or hepatic function. Healthcare professionals set the infusion rate and duration according to approved guidelines and patient response.

Safety data for levosimendan in pregnancy and lactation are limited. It is generally classified as a drug where the benefits must be weighed against potential risks. Clinicians should consider alternative therapies and discuss any potential exposure with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers preload and afterload, offering a distinct hemodynamic profile compared with agents such as dobutamine or dopamine.

Levosimendan Kalceks should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Levosimendan is administered intravenously, typically as a loading infusion followed by a continuous maintenance infusion. The exact rate and duration are set by the treating physician, and infusion should be performed under continuous cardiac and hemodynamic monitoring.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for blood pressure changes, ECG alterations, and any signs of allergic response throughout the infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving other potent vasodilators that could cause dangerous blood pressure drops. Caution is also advised in individuals with severe hepatic impairment or recent myocardial infarction.